Testicular cancer is the most frequent non-hematologic malignancy in young men aged between 18 and 40 years. Family history, infertility and cryptorchidism are risk factors. There is controversy about its association with microlithiasis [1, 2]. A painless mass is the typical presentation. In the setting of a metastatic disease, systemic symptoms or abdominal/back pain can predominate [2, 3].
90-95% are germ cell tumours (GCT) with 50% being seminomas and 50% non-seminomatous germ cell tumours (NS-GCTs, more frequent in patients < 30 years of age) [1, 2].
They primarily metastasise by lymphatic drainage and sometimes homogenously, most commonly to the lungs [3] and less commonly to the liver, bone and brain. Tumours of the right testis firstly drain to nodes around the inferior vena cava (IVC) and tumours of the left testis to nodes around the aorta: a regional disease. Nodes near the junction of the spermatic vein with IVC (on the right) and left renal vein (on the left) are the first stations [1, 2, 3]. Nodal disease superior to the renal hila occurs by direct spread [3]; and above the diaphragm is metastatic. NSGTs spread randomly in the mediastinum, pulmonary hilar and to neck lymph nodes [3].
Serum markers (beta-hCG, AFP and LDH) evaluate the burden of the disease, and can predict histology [1, 2]. In this specific case, embryonal and choriocarcinoma components justify the beta-hCG elevation.
US allows diagnosis of the primary tumour, and some findings can infer histology: NS-CGTs tend to be well-defined hypoechoic and heterogeneous, with cystic spaces and/or calcifications [1, 2]. Vascularisation, although suggestive, is not specific of malignancy [2, 3]. GCT may be small or involute even with metastases (“burned-out” tumours) [1, 2]. MRI is the option of choice when the diagnosis is in doubt [1].
Staging by the TNMS system determines management. The pathologic stage (T component) depends on histology of the resected tissue. The chest/abdomen/pelvis MDCT determines N and M components [1, 2]. Patients can also be stratified according to the International Germ Cell Tumour Consensus Conference Risk Classification [2, 3].
Retroperitoneal disease staging (N0-N3) depends on size criteria: nodes of 8mm or greater in less diameter are suspicious [1, 2, 3]. Newer techniques such as lymphotropic nanoparticle-enhanced MRI are under investigation for detecting metastases in nodes smaller than 10mm [2, 3].
The prognosis depends on early diagnosis and histologic type. NS-GCTs are treated with surgery and chemotherapy [2, 3].
Being familiar with the clinical manifestations, pathophysiology and radiologic findings allows a correct diagnosis, staging and management.